Table-III.
Menstrual Abnormality | P-value | ||
---|---|---|---|
| |||
Yes | No | ||
Sinovac | 30 (42.9%) | 40 (57.1%) | 0.15 |
Sinopharm | 14 (25.5%) | 41 (46.7%) | |
Pfizer | 8 (53.3%) | 7 (46.7%) | |
AstraZeneca | 5 (50%) | 5 (50%) | |
Moderna | 2 (50%) | 2 (50%) |
Menstrual Abnormality | P-value | ||
---|---|---|---|
| |||
Yes | No | ||
Sinovac | 30 (42.9%) | 40 (57.1%) | 0.15 |
Sinopharm | 14 (25.5%) | 41 (46.7%) | |
Pfizer | 8 (53.3%) | 7 (46.7%) | |
AstraZeneca | 5 (50%) | 5 (50%) | |
Moderna | 2 (50%) | 2 (50%) |